¬u²±¦~³ø´¦ÅS,2012¦~¥þ²y«e10¤jÃÄ«~,²Ä¤@¦WGSK,¨ä®ð³ÝÃĦ~¾P°âÃB¬°89»õ¬ü¤¸¡C²Ä¤G¦W¬°Abbot,¨äÃþ··ÃÃö¸`ª¢ÃĦ~¾P°âÃB¬°85»õ¬ü¤¸,³o¨â¶µÃĬҬ°¬u²±¥D¤O²£«~,¥]¬AAnti-Cemx, Xolair, Anti-IL6. ©Ò¥H¤@°_´Á«Ý¦~©³¨Îµ¡C
³oÓÀ³¸Ó¬O
adisinsight.springer.com/drugs/800032472
ª¬ºA¬ODiscontinued
Y¦³¿ù»~½Ð«ü¥¿
¤£¹L¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤Wµ¥©ó9000»õ¥x¹ô
¬u²±ªÑ¥»¤~30»õ¥x¹ô¡A¤@¦~eps¤£´N§Ö3000¤¸
±N¨ÓªÑ»ùÀ³¬O¦b30000¤¸³£ÁÙ¶û¤Ó§C
¦ý¥H²{¦bªÑ»ùnº¦5¿§Ú¤~¯à¸Ñ®M
¥u¨õ·L¦a½Ð¨DÅý§Ú¸Ñ®M§a
³Ñ¤Uªº§ÚÄ@·NÅý§O¤H¥hÁÈ
2.FB704(anti-IL6):
¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A¤w©M¦h®aÃļtñ©wCDA,¹wp¤µ¦~¦~©³¥Ó½Ð¬ü°êIND¡C§Ú»P¬ãµoªø³£¤£¬ù¦Ó¦Pªº»{¬°FB825¬O¬u²±ªºª÷Âû¥À¡C¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤W¡C¦pªG¦¨¥\±ÂÅv±N¬O¦¬¯q±NÃø¥H¦ôp¡C
cscs¤j¼gªº:
RocheªºQuilizumab°µ§¹¤G´Á¤£°µ¤F
¦Ó¤½¥q²{¦b¤~»¡FB825¤G´ÁÁ{§É¤~n¶}©l
¤Wz¬Ý¨Ó,,¬O¤£¬O¬Ý¨ìù¤óÃļtªºª¬ªp,©ì©µ2´ÁÁ{§É,¬Æ¦Ün©ñ±ó,
¦ý¤S¦bªÑªF·|¤W»¡¬Ý¦n
¥²³Ó¤j:§A»{¬°·|¤£·|¤S¬O¤@³õ¤jÄF§½¤F.¦]¬°§Ų́âÓ³£³QÄF©È¤F...«¢«¢«¢«¢
·íµM¤]nµ¥¤G´Á°µ§¹¤~ª¾¹D¦³¨S¦³®Ä¡A¥ú¥ÎFB825¡A´î¤Ö¦å²GIGEªº¿@«×«á¡A¹ê»Ú¯gª¬¤]¤£¤@©w¦³´î½w¡A
RocheªºQuilizumab´N¬O³o¼Ëªºµ²ªG¡C
FB825¸òRocheªºQuilizumab§¹¥þ¤£¦PªF¦è¡A¥u¬O·|»{¦PӼЪº¡A
¦U¦Ûµo®i¡A¤£¬OROCHE°µ§¹µ¹¥xÆW°µ¤G´Á¡C
¤TӤ뵹ÃĤ@¦¸¤£¬O¤°»òÀu¶Õ¡Atarget¤£¦P¡A¥Îªº¾¯¶q¤£¦P¡A
Anti-IL6¤]¨S¤°»ò¥Î¡A³o¤@ÓÄvª§ªÌ¦³¦h¤Ö¡A¬u²±¦³¤°»ò±j¶µ¯à¥´±oĹ?
§O¹ïFB¦³¤Ó¤jªº´Á±æ¤F
¦Ó¥B2´ÁÁÙ¨S¹L
¤WÂd¤§¤é¤]¬O»»»»µL´Á
n±ÂÅv°_½Xn®³¥XÁ{§É¼Æ¾Úµ¹°ê»ÚÃļt¬Ý
§Ú¬Ý¦³ªº©ì¤F
¦¤wº¡¨¼u¤Õ¡A¶Ë²ª²Ö²Ö
³o¤@ºjÁÙ®¼±o¦í
¥²³Ó¤j,¬O¤£¬O¤S³Q¥´¤@ºj¤F
½Ð±Ðfun¤jFB825TFDA2an²Ä¤G©u¶i¦æÁ{§É¹êÅç
¨ºì¹w©w¤µ¦~¤E¤ë§¹¦¨TFDA2a¤£¬O©µ¦Ü©ú¦~²Ä¤G©u¤~§¹¦¨¶Ü
1.FB825(Anti-C£`mX):
105¦~7¤ë»P¦h®aÃļtñ©w«O±K¨óijCDA ,¥Ø«e¤´¦b¨ó°Ó¤¤¡A°ê»Ú±ÂÅv¤@¯ë¨óij¥§¡¯Ó®É1¦~¥b®É¶¡¡C¹wp²Ä¤G©u¶i¦æ¥xÆWÁ{§É¤G´Á¹êÅç¡CFB825¾AÀ³¯g¬°²§¦ì©Ê¥Ö½§ª¢¡A¹w¦ô²§¦ì©Ê¥Ö½§ª¢ªº¥«³õ»ùȦÜ2022¦~¶È¦b¤E¤jÃÄ«~¥«³õ°ê«K±N¹F¨ì56»õ¬ü¤¸³W¼Ò¡CFDA¤µ¦~3¤ë©³®Ö㪺¥Íª«»s¾¯³æ®è§ÜÅéÃĪ«dupilumab¡A¥Î©óªvÀø¦¨¤H¤¤«×¨ì««×ªº²§¦ì©Ê¥Ö½§ª¢¡Cdupilumab»Ý¤@©P¥´¤@°w©Î¨â©P¥´¤@°w¡A¦ÓFB825¬°3Ӥ뵹ÃĤ@¦¸¡A¦]¦¹§ó¬°Àu²§¡C2.FB704(anti-IL6):
¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A¤w©M¦h®aÃļtñ©wCDA,¹wp¤µ¦~¦~©³¥Ó½Ð¬ü°êIND¡C§Ú»P¬ãµoªø³£¤£¬ù¦Ó¦Pªº»{¬°FB825¬O¬u²±ªºª÷Âû¥À¡C¤@¦~¾P°âª÷ÃB°ª¹F300»õ¬ü¤¸¥H¤W¡C¦pªG¦¨¥\±ÂÅv±N¬O¦¬¯q±NÃø¥H¦ôp¡C
3.FB317(Omalizumab¥Íª«¬Û¦üÃÄ):
¤µ¦~±N©ó¤¤°ê¤j³°¶i¦æPhase 1, omalizumab 2015¦~¥þ²y¾P°âÃB23»õ¬ü¤¸¥H¤W¡C
4.FB121(Ibalizumab¥Íª«¬Û¦üÃÄ):
¥Ø«e«ùÄò¶i¦æ¥Í²£»s¦¨Àu¤Æ¡C
5.SNA01»PSNA02(§ÜPD1»P§ÜPDL-1§K¬ÌÀˬdÂI¾AÅé·sÃÄ):
aptamer¬O¤@ºØ¯à»P¯S©wªº¥Ø¼Ð¤À¤lµ² ¦Xªº¹è®Ö苷»Ä(Oligonucleotide)¡C ¥Ø«ePD-1 ¸~½F§ÜÅé¤@¦¸Àøµ{¬ù15 ¸U¬üª÷( ªñ500 ¸U·s¥x¹ô)¡A¦ýPD-1 §ÜÅ骺¦³®Ä²v¥u¦³25 ∼ 30¢H¡A¾AÅ骺§Q°ò¦b©ó¨ä¦¨¥»¥u¦³§ÜÅ骺1/10¡A2020 ¦~PD-1 §K¬ÌÀˬdÂI¹w¦ôªº¥«³õ±N±µªñ100 »õ¬üª÷¡CSNA01»PSNA02¦b¤p¹«¹êÅ礤¦³¥§¡60%¸~½F§í¨îªí²{¡C
6.SNS01(tumor stem cell ):
°w¹ïªÍÀù·F²ÓM§ÜÅé·sÃÄ¡A²{¦b¶i¤J §ÜÅé¿z¿ï¡C¥«³õ¾P°â«O¦u¦ôp¨C¦~300»õ¬ü¤¸¡C
¤F¸Ñ§¹¬u²±©Ò¦³pipeline¶i«×¡AÓ¤H»{¬°³o®a¤½¥q«D±`Àu²§¨C¤@¶µ²£«~³£·¥¨ãÄvª§©Ê¡A¥«³õ¿W¦û©Ê¡C¬Æ¦Ü¥Ø«e³Ì¨üÆf¥ØÀù¯g§K¬ÌÀøªk¡A¬u²±§ó¬O°Ñ»P¨ä¤¤¡C¬u²±¥¼¨Ó¤£¥i¶q¡A±N·|¦b°ê»Ú¤jÃļt¶¡¹ñÅSÀY¨¤¡C
§ë¸ê¦Û¦³°ª·ÀI¡A½ÐÂÔ·V¦Û¦æµû¦ô¡A¶È¨Ñ°Ñ¦Ò¡C
°£¤F¬u²±ì¦³ªºFB825,FB704A, FB317, FB121¶i«×¤¶²Ð¥H¥~,¨Ö¤J¨ó©M·sÃÄ¥H«á,¨ä·sªºÃÄ«~¶}µo¼Ðªº&¶i«×¦³©Ò±Ôz¶Ü?
ÁÙ¬O¨â®a¦X¨Ö«á,¦nÅ¥¥s°µ¿i¦X´Á,ÃøÅ¥¥s°µ¨¤¤O´Á,©Ò¥H¨ó©M·sÃÄ즳ªºÃÄ«~¶}µo´N¥ýÀÁ¤@Ãä¤F!
¬u²±·s¸ê¥»ÃB¬°30»õ¡A
¤¤¤Ñ(¤¤¤Ñ+¦X¤@)64170±i=21.39%¡B
´I¨¹½²®a68273±i= 22.76%¡B
Æp¥Û(Æp¥Û+ºë^§ë¸ê(ªÑ)+Âײ±§ë¸ê(ªÑ))45777±i=15.26%,
¥x·s(¹Å¯E&Îë¥Ý) 5481±i(1.83%),
¥x¤j20649±i (=6.88%)
¥É¤s³Ð§ë3514±i (=1.17%)
¥H¤W¦Xp207864±i = 69.29%, ¤jªÑªF«ùªÑªñ¤C¦¨,µM«á©O!ü!
¦ü¥G¨S¶i¤J¸³ºÊ®u¦¸¡A
¤£ª¾¦³µL³B²z¡H
µ¥¥LPO
¥t½Ð±Ðª©¤W¦³¤H¥h°Ñ¥[ªÑªF·|©O? ¥i§_¤À¨É¤@¤U?ÁÂÁÂ!!
³Ì¦h«ùªÑ¨â¦Ê¤»¤Q±i¥ª¥k
©Ò©¯°±·l±o©y
§_«h¦A¹ï¤Á³s©R³£¨S¤F
¨S±Ï,¥H«á®£³£·|²_¬°¦¹¶°¹Î¥¼¤W¥«ÂdªÑ²¼
¥X³fªº¼Ðªº¤F
¤£¥Nªí¦hªÅ¥ß³õ
§Oµ¹§Ú¬ï¤p¾c
·sÃĶ}µo³¡¤À¡AºXÄ¥²£«~ FB825 ¶¶§Q¦b¬ü°ê§¹¦¨¤HÅéÁ{§É¤@´Á¸ÕÅç¡AÅã¥ÜÃÄ
ª«¦w¥þ©Ê¥BÃÒ¹êÃĪ«§@¥Î¾÷¨î¡A¸ÕÅçµ²ªG¤]®i²{ FB825 ªø®Ä©ÊªºÃĪ«Àu¶Õ¡AFB825
³q¹L TFDA ¼f¬dÀòã¶i¤JÁ{§É¤G´Á¸ÕÅç¶¥¬q¡C¥t¥H¡u¥þ¤HÃþ§ÜÅé®w¡v§Þ³N¦Û¦æ³Ð
·s¶}µoªº FB704A¡A¤w§¹¦¨©ñ¤j¥Í²£»sµ{¶}µo¡A¦¨¥\±N¦Û¦æ¶}µoªº¤ÀªR¤èªk¡B¾¯
«¬¡B¥H¤Î»sµ{§Þ³NÂಾ¦Ü¬ü°ê¦X§@ CMO ¼t¡A¶¶§Q§¹¦¨»s¦¨©ñ¤j¡A²{¤w¶i¤J GMP
¥Í²£»sµ{¶}µo¶¥¬q¡A¹wp 106 ¦~¤U¥b¦~¦V¬ü°ê FDA ¥Ó½Ð·sÃÄÁ{§É³\¥i¡Cµ¦²¤§G§½
¤¤°ê¥«³õªº¥Íª«¬Û¦üÃÄ FB317¡A¤wÀò±o¤¤°ê CFDA ·sÃÄÁ{§É¸ÕÅç³\¥i¡A¶}©l°õ¦æ
Á{§É¸ÕÅç¡A¨Ã¿n·¥»P¦X§@¹Ù¦ñ¦@¦P¶}³Ð¤¤°ê¥«³õ¡CªvÀø·R´þ¯fªº¥Íª«¬Û¦üÃÄ
FB121¡A«ùÄòÀu¤Æ¥Í²£»sµ{¶}µo¡A°§C¥Í²£¦¨¥»¡A²{¥iª½±µ¶i¦æ¥Í²£»sµ{©ñ¤j¡A
¥[³t¶}µo®Éµ{¡A¥i±æ¹Å´f§ó¦hªº·R´þ¯f±w¡C
¬ã¨sµo®i¦¨ªG»¡©ú
¥»¤½¥q¥DnÃĪ«¶}µopµe¤À¶µ»¡©ú¦p¤U¡G
(1)FB825 (Anti-C£`mX)§ÜÅé·sÃÄ
FB825 ¬ãµo¦¨ªG·J¾ã¦p¤U¡G(a)¥þ²y±M§Q§G§½¡G¤w³°Äò¨ú±o¬ü°ê¡B«n«D¡B
¿D¤j§Q¨È¡B¥H¦â¦C¡B¤¤°ê¡B»´ä¡B¿Dªù¡B¦L¥§¡B¤é¥»¡BÁú°ê¡B«Xù´µ¡B·s
¥[©Y¡B¾¥¦èôµ¥¦h°ê±M§Q¡A©|¦³¥]§t¼Ú¬wµ¥°ê±M§Q«ùÄò¥Ó½Ð¤¤¡A¤w³v¨B§¹
¦¨¦¹¶µÃöÁä©Ê·sÃĤ§¥þ²y±M§Q«OÅ@³Êªº«Øºc¡C(b)¾¯«¬¶}µo¡G¤w§¹¦¨ÀR¯ßª`
®g©M¥Ö¤Uª`®g¨âºØ¾¯«¬ªº¶}µo¡A±N¦³§U©ó«áÄò·sÃÄÁ{§É¸ÕÅç¥Ó½Ð»PÃĪ«À³
¥Î½d³òªºÂX®i¡C(c)¬ì±Mpµe°õ¦æ¡G¤w¨ú±o¨Ã§¹¦¨¨â´Á¸gÀÙ³¡¬ì§Þ¬ã¨sµo®i
±M®×pµe¡A¦¨¥\¨ú±o¸gÀÙ³¡¤§¬ì±Mpµe¸É§U·s¥x¹ô 5,700 ¸U¾l¤¸¡A°õ¦æ¦¨
®Ä³Æ¨ü¸gÀÙ³¡ªÖ©w¡C(d)Á{§É¸ÕÅç°õ¦æ¡G¤w¶¶§Q§¹¦¨¬ü°ê FDA ·sÃĤ@´ÁÁ{
§É¸ÕÅç¡AÀò±o«nÁ{§É¼Æ¾Ú¡A¨ÃÀò TFDA ®Öã¶i¤J¤HÅéÁ{§É¤G´Á¸ÕÅç¡C
FB825 §ÜÅé¬O·s¤@¥NªvÀø¹L±Ó¯e¯fªº§ÜÅé·sÃÄ¡C¬Û¸û©ó Omalizumab
¥Dn¥\¯à¬°¤¤©M¦å¤¤´åÂ÷ªº IgE¡AFB825 ¨ã¦³·s¿oÃIJz¾÷¨î¡A¥¦¯à³z¹L»¤
¾É²ÓMä¤`©M§ÜÅé¨Ì¿à©Ê²ÓM¬r±þ§@¥Îµ¥¾÷¨î§í±þªí²{½¤Æ^´O«¬ IgE ªº B
²O¤Ú²ÓM (mIgE-B ²ÓM)¡A±q¤W´åªýÂ_ IgE ªº¤Àªc¡A¹F¦¨¹L±Ó¯e¯fªºªvÀø
»P¹w¨¾¡C©ó¤@´ÁÁ{§É¸ÕÅ礤®i²{ÃĪ«¦w¥þ©Ê¥H¤ÎÃÒ¹êÃĪ«§@¥Î¾÷¨î¡C
¦¹¥~¡A»P¥þ²y°ß¤@®Öã¥Î©ó¤¤««×®ð³ÝªvÀøªº§ÜÅéÃĪ« Omalizumab
¬Û¤ñ¸û¡AFB825 §ÜÅé·sÃĨ㦳¥H¤U¦h¶µ¼ç¦bµo®i§Q°ò»P°Ó¤ÆÀu¶Õ¡G
A.¤¬¸É©Ê¡GÀ±¸É°ª IgE ªí²{¯f±w(>1500IU/ml)ªºªvÀø¯Ê¤f¡C
B.¿W¯S©Ê¡GÃIJz¾÷¨î¿W¯S¡B©ú½T¡C
C.¥[¼©Ê¡G©M Omalizumab ¨Ö¥Î¡A¥i´î§CÃĪ«¥Î¶q¡A¹F¦¨³Ì¨ÎÀø®Ä¡C
D.¹w¨¾©Ê¡G¥i¥Î©ó©u¸`©Ê¹L±Ó¯e¯f¤§¹w¨¾¡C
E.¼sªx©Ê¡G¾AÀ³¯g¸û Omalizumab §ó¬°¼e¼s¡A¥i¾A¥Î©ó§ó¦hªº¹L±Ó©M®ð³Ý
±wªÌ¡C
F.ªø®Ä©Ê¡G¥Ñ¤@´Á¸ÕÅç¼Æ¾Ú±À´ú¡AFB825 ±N¥i¯à 3 Ӥ뵹ÃĤ@¦¸¡A±N¤j´T
°§CÂåÀøt¾á¡A¼W¥[¨Ï¥Î¤è«K©Ê
(2)FB704A (Anti-IL6) ¥þ¤H§ÜÅé·sÃÄ
FB704A ¬O¥»¤½¥q§¹¥þ¦Û¥D¶}µoªº³æ®è§ÜÅé·sÃÄ¡A¹B¥Î¦Û«Ø¤§¡u¥þ¤H
Ãþ§ÜÅé®w¡v¡A¤w§¹¦¨§ÜÅé¿z¿ï¡B®Ä»ù´£¤É¡B³J¥Õ½è¤Î²ÓM¼h¯Å¥\¯à©Ê©M¦w
¥þ©ÊÅçÃÒ¡B°ª²£¶q²ÓM®è«Øºc¡B¤W¡B¤U´å»sµ{¶}µoµ¥ÃöÁä¶}µo¤u§@¡C³z¹L
³æ¾¯¶qÆFªøÃþ¬r²z¸ÕÅç¡Aªì¨BÃÒ¹êÃĪ«¦w¥þ©Ê»P¥b°I´Á¡A¬Ò³q¹LÃĪ«µo®i
ªùÂe¡A¤j´T°§CÃĪ«¦w¥þ©ÊªººÃ¼{¡C¥»¦~«×§¹¦¨»sµ{©ñ¤j¸Õ²£¡A²£«~«~½è
¤ÀªR¡A¨Ã±Ò°Ê¦h¾¯¶qÆFªøÃþ°Êª«ÃÄ¡B¬r²z¸ÕÅç¡C±M§Q¥Ó½Ð³¡¤À¡AFB704A
¥þ¤H§ÜÅé·sÃĤw¨ú±o¥xÆW¤Î¬ü°ê±M§Q®Öã¡A¥B¥Ñ PCT l¦ù·s¼W¤C°ê¤§¥¿¦¡
±M§Q¼f¬d¡A¨Ã±N³z¹L¾¯«¬¶}µo©M¾AÀ³¯gÂX®iµ¥¤è¦¡¡A±j¤Æ±M§Q«OÅ@½d³ò»P
©µªø±M§Q«OÅ@®É¡C
FB704A ¸g¥Ñ¦h¶µÂ÷Åé¡B¬¡Åé¥\¯àÅçÃÒ¸ÕÅçµ²ªGÃÒ¹ê¡AFB704A ¥Íª«¬¡
©ÊÀu©óù¤ó»sÃĤw¤W¥«¾P°â¤§ÀÀ¤H¤Æ§Ü IL6 ¨üÅ骺 Tocilizumab¡A¥]¬A¦h¶µ
§K¬Ì½Õ¸`¸ÕÅçÃÒ¹ê FB704A ¯à¦³®Ä§í¨î¤HÃþ¦h¾ã²ÓM¤Àªc«Pµoª¢¿E¯ÀÄÀ©ñ
ªº¬¡©Ê¡Aª½±µÅçÃÒ FB704A ¨ã¦³Àu©ó Tocilizumab ªvÀøÃþ·Àã©ÊÃö¸`ª¢¤§
¼ç¤O¡C¦b§í¨îÀù¯gªº¯e¯f¼Ò¦¡´ú¸Õ¤¤¡AÃÒ¹ê FB704A ¤£¶È¥i¦³®Ä§í¨î¦åºÞ
·s¥Í¤Î¸~½FÂಾ¡A¨Ã¤j´T´î½wÀù¯g´c¯f½è©Ò³y¦¨ªºÅé«´î»´¡A¦P®É¦³®Ä´£
¤É¸~½F¤p¹«ªº¦s¬¡²v¡A¤S FB704A ¸g¹L¤@¨t¦C²ÓMµ²¦X¤ÀªR¡B²ÓM¿E¯ÀÄÀ
©ñ¡B·»¦å´ú¸Õµ¥¦w¥þ©Ê¸ÕÅç¡AÃÒ©ú¦w¥þ©Ê·¥¨Î¡C
¤¶¥Õ¯À 6 (IL6)¬OÅ餺«D±`«nªº§K¬Ì½Õ±±»P²ÓM¼W¥Í«P¶i¦]¤l¡C®Ú¾Ú
¬ì¾Ç¤åÄm³ø¾É¡A¤wª¾ IL6 »P¦h¶µ¯e¯fµo¥Í¾÷Â঳Ãö¡A¬O¥Ø«e¸ó°ê¤jÃļt¥þ
¤O¶}µo¤§ÃĪ«¼Ðªº¡CFB704A ¥Ø¼Ð±ÂÅv¤jÃļt¦@¦P¬ãµo¡A³W¹º 106 ¦~¤U¥b
¦~¦b¬ü°ê´£¥X·sÃÄÁ{§É¸ÕÅç(IND)¥Ó½Ð¡A¥[³t®ÖãÀ³¥Î©óÃþ··Ã©ÊÃö¸`ª¢
ªvÀø¤§§Ü IL6 ¥þ¤H§ÜÅé·sÃÄ¡A¨Ã¿n·¥±´¯Á¨ä¥L¾AÀ³¯g¡A¼W¥[ÃĪ«¥«³õ»ùÈ¡C
(3)FB121 (Ibalizumab ¥Íª«¬Û¦üÃÄ)
FB121 ¬°ªvÀø·R´þ¯f¬r(HIV)·P¬V¯gªº§ÜÅéÃĪ«¡A§@¥Î¼Ðªº¬°¤HÃþ T
²ÓMªí±ªº CD4 ¤À¤l¡ACD4 ¬O·R´þ¯f¬r·P¬V¥²nªº½¤³J¥Õ¤§¤@¡CFB121
§ÜÅéµ²¦X CD4 «á¡AªýÂ_·R´þ¯f¬r¶i¤J T ²ÓMªº²ÓM¿Ä¦X§@¥Î¡AÂǦ¹¨¾¤î
·P¬V¡A¹F¦¨ªvÀø¥Øªº¡CFB121 ¬°§Ü CD4 §ÜÅéÃĪ«¡A¤£·|´î·l T ²ÓM¦Ó¶Ë
®`¯f±w¯Ü®zªº§K¬Ì¨t²Î¡A¨ã¦³¼sªx¯f¬r§í¨î¯à¤O¡C
¥»¤½¥q¬ð¯}§Þ³NªùÂe¡AÀ³¥Î¦Û¦æ
Á{®ÉªÑªF·|¡A¤f¤fÁnÁn»¡´«ªÑ¤ñ¨Ò¨S°ÝÃD¡A¦ý½M¤l³£¬Ýªº¥X¨Ó°ÝÃD«Ü¤j¡Aµ²ªG¨Æ¹êÃÒ©ú¡A´«ªÑ«á±q22¶^¨ì17¤¸(¨ì¥Ø«e¬°¤î)....
§Ú«e±¤]»¡¡A³Ì¤j°ÝÃD¬O¤½¥q¦Û¤v¤]»{¬°¥Ø«eªºÃÄ¡A¥«Èµ¥©ó¹s(½Ð°Ñ¦Ò«e±ºâªk)¡A¤~·|¥Î22¤¸·í§@¦Û¤vªº¥«È
Y¨S¦³¹Ï§Q¨ó©M¤jªÑªF¬O¨Æ¹ê¡A¨º´N¬O©Ó»{¦Û¤vªºÃĤw¸g¨S»ùÈ¡A¨º¤½¥qÁÙÀç¹B¥¿±`¶ÜXDD
¬u²±¤w¦¨¬°¨ó©M¤jªÑªFªº´£´Ú¾÷¤F
10-15¤¸ªº¬u²±,¥¼¨Ó¤£¤[©Î³\·|¬Ý¨ì
¥x¼t°Ñ¥[¼¯®Ú¤j³q°ê»Ú¥ÍÂå¦~·|¡]J.P. Morgan Healthcare Conference¡^¶Ç¨Ó³ß°T¡A¥]¬Aù¤ó¡B¼b¥Í¡B§¨Ó¡B¿ÕµØµ¥°ê»Ú¤@½u¤j¼t¶}¥X±ø¥ó¡A±N§ÞÂà¥x¼t§ÜÅéÃIJ£«~¡A¨ä¤¤¬u²±¡B¦X¤@µ¥¤½¥qªº²£«~§Þ³N¸ß°Ý«×°ª¡A³Ì§Ö¥»©u¥i±æÃ±q±ÂÅv¨óij¡C
¬°¦ó¿ð¿ð¨S¤U¤å¡H§Ú²q³Ì¦³¥i¯àªºµo®i¬O¡A¤¤¤Ñnªº±ÂÅvª÷¡A¸ò¬u²±ªº¥«È®t¶Z¹L»·¡A¤£Ä@·N¦¨¬°©Ô©ïªÑ»ùªºª£¤â¡A©Ò¥H¡A¤@ª½¨S¦³¥æ¶°¡ã
¬JµM¤w¸g¤W¥«Äw¸ê¡Aºû«ùªÑ»ù¦X²z©Ê¥»¨Ó´N¬O¤½¥qªº¸q°È¡Aµ²ªG·d¨ì³s½Í§P³£¨ü¨ì¼vÅT¡A³o¥s°µ°½Âû¤£µÛ»k§â¦Ì¡ã
¬u²±·í®É¤W¥«»ù®æ¬O40¤¸¡A¤]´N¬O¤½¥q»{¬°¤½¥qªºÃÄ¡A»ùȬ°15X4.0-15(²{ª÷)=45»õ¡C³Ìªñ¸ò¨ó¦X¦X¨Ö¡A22X1.5-12(²{ª÷)-21(Æp¥Û¥Í§Þ¼ç¦b»ùÈ)¡×0 ¬Ý¨ì¨S¦³¡A¤½¥q»{¬°¤â¤Wªº·sÃÄ¡A²{¦b¤@ÂI»ùȳ£¨S¦³¡A§AÌ·í¤jÃļtªº·|p¬O¶Ì³J¶Ü¡H
Yªñ´Á¯à½Í¨ì±ÂÅv¡A§Ú²q±ø¥ó¤@©wÄê¨ìÃø¥H·Q¹³¢æ¢Ò¡A§AÌ´NÄ~ÄòÀ£§CªÑ»ù§a¡ã
¦pªG¥ìÁÙ¦bªº¸Ü¡AÆp¥Û¥Í§Þn¤W¥«¡AªÑ»ù¤@©wn©Ô©ï¡A§Ú²q´ú·|¥X¤¤¸Î¯E¹©¨Ó©Ô¬u²±¡A¥u¬O¦Ü¤ÖÁÙ¦³¤»Ó¤ëªº®É¶¡¡A¦ó®É·|¶}©l¹B§@¡A´NÃøÁ¿¤F¡ã
¸ò¥ý«e¤@¼Ë¡A¥u¯àµ¥±ÂÅv¡A©Î¬OÆp¥Û¥Í§Þ¤W¥«ªº¦n®ø®§¡A³o¬q®É¶¡¡A´NÅý¤j¤á¦Û¤vª±§a~
±þ«Ü¤j
¥t¥~FB317±q2016/6¤ë®³¨ìCFDA¤@´Áªº¥Ó½Ð& FB704A¤@ª½°±¯d¦bÁ{§É«e,¯u§Æ±æ¤µ¦~ªÑªF·|FB317 &FB704A¦³¶i¤@¨Bµo®iªº®ø®§!
§ÚÅ¥¨ìªº¤K¨ö¬O¡A¥»¨Ó³oÓ±i³Õ¤h¬O¤£¥´ºâ¶}µo¤U¥h¡A¦Ü©ó¬°¦ó¤£¶}µo¡A¬Æ¦Ü¬°¦ó²{¦b·|®³¥X¨Ó¶}µo¡A§Ú´N¤£²M·¡¤F¡]§ÚÓ¤H¬O²q´ú¡A¢Ô¢Ð825¬OÀu©óub221¡A¤¤¶¡²£«~·íµM´N¥ý©ñ±ó¡A°£«D¢Ô¢Ð825¥¢±Ñ¡A¤~·|«·s¦Ò¼{®³¥X¨Ó¬ãµo¡CÁp¥ÍÃĬO·s¤½¥q¡A¨S¦³FB825¡A·íµM·|·Q®³¥t¤@Ó¨Ó¬ãµo¡A¥un¦¨¥\¡AÁÙ¬O·|ÁÈ¡^
¥LÌn¸¹ºÙ¥|¥N¡A¤¥N¡A¤]¤£·|¦³¤H¥X¨Ó¤Ï»é¡A²¦³ºµo©úªÌ³£¬O±i¤l¤å¡A°ò©ó§¼Æ¬u²±À³¸Ó¤]µLªk¦h»¡¨Ç¤°»ò§a¡ã
¡An¬Ý¥¼¨Ó«ÅºÙ¾AÀ³¯g¬°¦ó¡H
FB825«ÅºÙ¾AÀ³¯g¬°²§¦ì©Ê¥Ö½§ª¢¡A¤w¦bTFDA¤G´Á¡AUB-221¤µ¦~²Ä¥|©un¥Ó½ÐFDA¤@´Á¡A¦³
¥i¯à¬O¦b¤£¦Pªº¶]¹DÁɶ]§a¡I
Y¬Oª£ªÑªÌ¡A´«¤â§¹«á¡A§A·|µo²{·s»D¯à¨£«×¡A¬ðµM¼W¥[¤£¤Ö¡A±µµÛªÑ»ù½wºC¤W¤É¡AµM«á¡A¤@Ó¤j§Q¦h¡AÃz¶q¤Wº¦¡A´N±µªñ§ÀÁn¤F¡C
¬OþºØ¡A´N¬Ý¬O½Ö±µ¨«¤F¡ã
¤¤ë¥|¤é«á¦¨¥æ¶q³vº¥©ñ¤j¡A¥Ø«eÀ³¬O¤ÏÀ³
Äw½X±§QªÅ¡A¤£ª¾¬O§_¬°§Þ³NªÑ¥X²æ¡H¤p½Þ
¤jªº¸Ü·¥¦³¹D²z¡A¤Q¦h¤¸ªº¬u²±¡AY¬O¬Ý¦n
FB825ªº«e´º¡A§Q¼í¤j©ó·ÀIªº¾÷·|¸û¤j¡C
©Ò¥H¡A§Ú»¡Y§A¬Ý¦nFB825¯à¦¨¡A²{¦b»ù¦ì¤w¸g·í°µ¥L¥¢±Ñ¡AY¦¨¥\¡A´N·|¼Éº¦¡A¥¢±Ñ¡AÁÙ¦³¨ä¥L·sÃij»µÛ¡A¥Hªø®É¶¡¨Ó¬Ý¡A½ß¿ú¾÷·|¤p¡A¦ýÀò§Q¦³¾÷·|¦n´X¿¡A¦³¤°»ò¤ñ³oºØ§ë¸ê¾÷·|¦n¡H
¦ý¡A°O±on¥Î¶¢¿ú¡A¦Ü¤Ö¦³µ¥¤T¡ã¤¦~ªº¨M¤ß¡A·íµM¡AY¤¤¶¡¬ðµMµo»Ã¡A¥i¥H´N¥áµ¹¨ä¥L¤H±µ¤F¡ã
¤ßùتº·Î¼õ¡A¤ñ½ß¿ú§ó¥i©È¡A§NÀR§ä¥X
¦³§Qªºµ¦²¤§a¡I
®Ú¾Ú¸ê®Æ¨Ó¬Ý¡A¦X¨Ö«áÆp¥Û¥Í§Þ¾Ö¦³¬u²±40%¡A¦Ó¤¨¦Ñ¾Ö¦³Æp¥Û¥Í§Þ¡AYÆp¥Û¦~©³n¤W¥«¡A¬°¤F©Ô°ªµo¦æ»ù®æ¡A¬u²±ªÑ»ù·|Ãø¬Ý¶Ü¡H°£«D³o´X¤Ñ¬O¤¨¦Ñ½æ¦^µ¹¨ä¥LªÑªF¡A¨º´N¨SÔ£¦n´Á«Ý¤F¡ã
°ò¥»¤W¡AY¬Ý¦nFB825¡A¦³¶¢¿ú´N¥[½X¡A¥H¥Ø«eªÑ»ùº¦Ó¤¿¤£¬OÃø¨Æ¡A´Nºâ¥Î®É¶¡³ø¹S¨Ó¬Ý¡A¥xªÑ¤]¨S´X°¦¥i¥H¦³³o¼ç¤O¡A«ÂI¬O¡A§An¨IµÛ¦í®ð¡A§O¤¤³~³Q¬~±¼¡C
¥t¥~¡A¤]¦]¬°ªÑ»ù³Q¾Þ±±¡Aþ¤Ñ§Q¦h«e¦³¤H¤jÁ|¶R¶i¡A¨º´N¥i¥H¥hÃÒºÞ·|¥hÀËÁ|¡AªÑ»ùªø´Á±´©³¡A«ç»ò¥i¯à¬ðµM¤£p»ù®æ¤j¶q¶R¶i¡A¤j¶q¶R¶iªÌµ´¹ï¬O¤º½u¥æ©ö¡C©Ò¥H¡A¥LÌn¶R¡A¤]¥u¯à¶X§Q¦h«e¡AÀ£§CºCºC¦Y³f¡A¤½¥¬§Q¦h«á¡A¤@¤Ñº¦¨¬¡A´²¤á·Q¶R¤S±o°ª»ù¶R¤F¡ã
Á{§É2©Î3´Á¤~¶i³õ,¥i¥H¬Ù±¼N¦~®É¶¡¦¨¥»
¤¤¸Î ¯E¹©¤]¬O¦p¦¹
®É¶¡¦¨¥»À³¸Ó¤]¬O§ë¸êªº¾÷·|¦¨¥»¨ä¤¤¤@¶µ
¦³®É¶¡§Ú¦A¥J²Ó¬ã¨s¨ó©Mªº§ÜÀùÃĦ³¦ó§Q°ò
³Ìªñªº¶iµ{À³¸Ó¬O9¤ë1¤é«áFB825 2aµ²ªG
½ß¿ú¤]¥u¯à©Ç¦Û¤v¾ÇÃÀ¤£ºë¤F
¦pªGµ¥«Ýªºµ²ªG,¦³¦p¤¤¸Î,¯E¹©ªº¤@¤jªi±j涨,ȱo
¦ý¦p¬Û¤Ï,¨º......
§O§Ñ¤F,¥un¬O¤¤¤Ñ¶°¹ÎªºªÑ²¼,³£¤£¤j·|º¦
¦¹¤ä¬O§_·|¨Ò¥~,,,,
½ÍÅÊ·R¡A»¡ªº´N¬O³oºØ±¡§Î¡A¬Ý¿ù¤è¦V¤H¤H³£·|¡A
«ÂI¦b©ó×¥¿»PÀ˰Q¡A§ë¸êªº¥Øªº´N¬OÁÈ¿ú¡A§O¾E
«ã©ó©M§A«ù¬Û¤Ï¤è¦Vªº¤H¡A¦h¤Ö¸q¥¿ÃãÄYªº¨¥»y¡A
¤£¹L¦b±»¹¢¦Û¤v¬Ý¿ù¤è¦V¡AªÑ¤Í³\¦hÄ_¶Qªº¸ê°T¡A
§Ú³£¬Û·í«µø¡A¹ï¿ù»P»ùȧPÂ_¨ú¨M©ó¦Û¤v¡C